secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001326190-24-000053
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports pemvidutide Phase 1b MASLD data: LFC reduced up to 68.5%
--------------------------------------------------------------------------

- Pemvidutide reduced liver fat content (LFC) by up to 68.5% from baseline over 12 weeks in 94 MASLD patients.
- Total cholesterol decreased by up to 12.2% and triglycerides by up to 44.6% after 12 weeks of treatment.
- Presented at AASLD The Liver Meeting from a 12-week Phase 1b trial in overweight/obese MASLD subjects.
- Subjects received once-weekly subcutaneous pemvidutide (1.2mg, 1.8mg, 2.4mg) or placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000053/0001326190-24-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000053/alt-20241115x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-24-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer